Abstract
A convenient remotely-controlled synthesis of no-carrier-added sodium [18F]fluoroacetate is described. Three ethyl esters 1a- 1c and three t-butyl esters 3a-3c containing either a methanesulfonyloxy- (OMs), p-toluenesulfonyloxy- (OTs) or p-nitrobenzenesulfonyloxy (ONs) leaving group were investigated as labeling precursors. The optimized radiosynthesis of n.c.a. sodium [18F]fluoroacetate was performed in two steps: (1) Incorporation of fluorine into (methanesulfonyloxy)-acetic acid t-butyl ester 3a as the superior labeling precursor in CH3CN at 100 ° C for 5 min followed by (2) acidic hydrolysis of the resulting [18F]fluoroacetic acid t-butyl ester at 100 ° C for 10 min to afford [18F]fluoroacetic acid. Several consecutive purification steps using anion exchange cartridges (Alltech Maxi-Clean SAX) and Sep-Pak neutral alumina cartridges gave sodium [18F]fluoroacetate in reproducible radiochemical yields of 20-25% (decay-corrected, n=20) in high radiochemical purity ( > 99%) within 50 min. Radiopharmacological characterization of sodium [18F]fluoroacetate was studied in Wistar rats and HT-29 tumor-bearing mice in comparison with [11C]acetate.
Keywords: 18F-labelling, [18F]fluoroacetate, positron emission tomography (PET)
Current Radiopharmaceuticals
Title: Radiosynthesis of N.C.A. Sodium [18F]Fluoroacetate and Radiopharmacological Characterization in Rats and Tumor-Xenografted Mice
Volume: 1 Issue: 2
Author(s): S. Richter, R. Bergmann, J. Pietzsch, B. Beuthien-Baumann and F. Wuest
Affiliation:
Keywords: 18F-labelling, [18F]fluoroacetate, positron emission tomography (PET)
Abstract: A convenient remotely-controlled synthesis of no-carrier-added sodium [18F]fluoroacetate is described. Three ethyl esters 1a- 1c and three t-butyl esters 3a-3c containing either a methanesulfonyloxy- (OMs), p-toluenesulfonyloxy- (OTs) or p-nitrobenzenesulfonyloxy (ONs) leaving group were investigated as labeling precursors. The optimized radiosynthesis of n.c.a. sodium [18F]fluoroacetate was performed in two steps: (1) Incorporation of fluorine into (methanesulfonyloxy)-acetic acid t-butyl ester 3a as the superior labeling precursor in CH3CN at 100 ° C for 5 min followed by (2) acidic hydrolysis of the resulting [18F]fluoroacetic acid t-butyl ester at 100 ° C for 10 min to afford [18F]fluoroacetic acid. Several consecutive purification steps using anion exchange cartridges (Alltech Maxi-Clean SAX) and Sep-Pak neutral alumina cartridges gave sodium [18F]fluoroacetate in reproducible radiochemical yields of 20-25% (decay-corrected, n=20) in high radiochemical purity ( > 99%) within 50 min. Radiopharmacological characterization of sodium [18F]fluoroacetate was studied in Wistar rats and HT-29 tumor-bearing mice in comparison with [11C]acetate.
Export Options
About this article
Cite this article as:
Richter S., Bergmann R., Pietzsch J., Beuthien-Baumann B. and Wuest F., Radiosynthesis of N.C.A. Sodium [18F]Fluoroacetate and Radiopharmacological Characterization in Rats and Tumor-Xenografted Mice, Current Radiopharmaceuticals 2008; 1 (2) . https://dx.doi.org/10.2174/1874471010801020103
DOI https://dx.doi.org/10.2174/1874471010801020103 |
Print ISSN 1874-4710 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4729 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Molecular Chaperone Activity and Biological Regulatory Actions of the TPR-Domain Immunophilins FKBP51 and FKBP52
Current Protein & Peptide Science Clinical Potential of VIP by Modified Pharmaco-kinetics and Delivery Mechanisms
Endocrine, Metabolic & Immune Disorders - Drug Targets Methylenetetrahydrofolate Reductase (MTHFR): A Novel Target for Cancer Therapy
Current Pharmaceutical Design 3-Carboranyl Thymidine Analogues (3CTAs) and Other Boronated Nucleosides for Boron Neutron Capture Therapy
Anti-Cancer Agents in Medicinal Chemistry Molecular Signatures of Biomarkers in Cancer Development, Diagn osis, and its Prognostic Accuracy
Current Biomarkers (Discontinued) Insights into Interactions of Human Cytochrome P450 17A1: A Review
Current Drug Metabolism Epstein-Barr Virus-associated Gastric Cancer and Potential Mechanisms of Oncogenesis
Current Cancer Drug Targets Saponins as Tool for Improved Targeted Tumor Therapies
Current Drug Targets Epidermal Growth Factor Receptor Inhibitors: A New Prospective in the Treatment of Lung Cancer
Current Medicinal Chemistry - Anti-Cancer Agents Src Family Kinases as Regulators of Angiogenesis: Therapeutic Implications
Current Cancer Therapy Reviews Apoptotic and Anti-Angiogenic Effects of Benzimidazole Compounds: Relationship with Oxidative Stress Mediated Ischemia/Reperfusion Injury in Rat Hind Limb
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Targeted Toxins for Glioblastoma Multiforme: Pre-Clinical Studies and Clinical Implementation
Anti-Cancer Agents in Medicinal Chemistry The Transcription Factor ETS-1: Its Role in Tumour Development and Strategies for its Inhibition
Mini-Reviews in Medicinal Chemistry Epidemiology, Clinical Presentation and Treatment of Mucosal Melanoma
Clinical Cancer Drugs Systemic and Biophase Bioavailability and Pharmacokinetics of Nanoparticulate Drug Delivery Systems
Current Drug Delivery Commercial Availability of Alpha-Emitting Radionuclides for Medicine
Current Radiopharmaceuticals PARP Inhibitors in Ovarian Cancer
Recent Patents on Anti-Cancer Drug Discovery Tocotrienols and Cancer: From the State of the Art to Promising Novel Patents
Recent Patents on Anti-Cancer Drug Discovery Chemoprevention of Cancer by Isothiocyanates and Anthocyanins: Mechanisms of Action and Structure-Activity Relationship
Current Medicinal Chemistry DNA Microarray-Based Gene Expression Profiling in Cancer: Aiding Cancer Diagnosis, Assessing Prognosis and Predicting Response to Therapy
Current Pharmacogenomics